Am­gen's Neu­las­ta gains an­oth­er biosim­i­lar com­peti­tor as sales slip

Neu­las­ta, one of Am­gen’s old­est drug fran­chis­es, has an­oth­er biosim­i­lar to con­tend with.

Ger­man phar­ma Fre­se­nius Kabi an­nounced on Tues­day that the FDA has ap­proved its peg­fil­gras­tim biosim­i­lar, to be mar­ket­ed as Stimufend. The drug will add to a grow­ing ar­se­nal of biosim­i­lars used to treat neu­trope­nia, a con­di­tion com­mon among chemother­a­py pa­tients where neu­trophils, a type of white blood cell, are too low.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.